Phillip Low, PhD | Authors

Phillip S. Low, PhD, Discusses Next Steps in Research of 177Lu-PSMA-617 for mCRPC and Other Cancers

April 14, 2022

Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.

Medical World News® Inside the Practice: Phillip Low, PhD, on the Development and Approval of Pafolacianine

January 30, 2022

CancerNetwork® spoke with Phillip Low, PhD, about the development and FDA approval of pafolacianine.